chartexchange

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

GlobeNewswire Inc. | Oct 1, 2026 7:00 AM EDT

Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials

Read original article